This profile has not been claimed and data may not be accurate.
Founder275
73rd percentile
Investor0
YC S14Serial FounderUnicorn FounderIPORaised $50M+
Founder Matrix
Most Complimentary
Credibility
this founder typical founder (50th pct)
Operator · 98th percentile
- Current co-founder and CEO of Ginkgo Bioworks, active since August 2008.
- Current co-founder of Joyn Bio, listed as an active founder role on LinkedIn.
- Ginkgo Bioworks is a Y Combinator Summer 2014 alum.
- Past founder signal confirmed across multiple companies including Ginkgo Bioworks and Allonnia.
- Ginkgo Bioworks was co-founded with multiple co-founders alongside Jason Kelly.
- Wikidata entity Q114874203 exists for Jason Kelly, confirming public notability as CEO of Ginkgo Bioworks.
Founder score
- 97%Probability of being accurate (97%)Current co-founder and CEO of Ginkgo Bioworks, active since August 2008.
- 95%Probability of being accurate (95%)Ginkgo Bioworks is a Y Combinator Summer 2014 alum.
- 90%Probability of being accurate (90%)Ginkgo Bioworks went public via SPAC merger in 2021, representing a distinct founder exit.
- 90%Probability of being accurate (90%)Past founder signal confirmed across multiple companies including Ginkgo Bioworks and Allonnia.
- 88%Probability of being accurate (88%)Raised approximately $67.94M in total across Ginkgo Bioworks ($51.6M per SEC Form D), Allonnia ($16.3M per SEC Form D), and Mad About Grain ($40k per SEC Form D).
- 88%Probability of being accurate (88%)Ginkgo Bioworks was co-founded with multiple co-founders alongside Jason Kelly.
- 85%Probability of being accurate (85%)Wikidata entity Q114874203 exists for Jason Kelly, confirming public notability as CEO of Ginkgo Bioworks.
- 82%Probability of being accurate (82%)Current co-founder of Joyn Bio, listed as an active founder role on LinkedIn.
- 55%Probability of being accurate (55%)Ginkgo Bioworks is a publicly traded company (NYSE: DNA), confirming current profitability or public-company status as a public signal.
- 35%Probability of being accurate (35%)Stack Overflow reputation of 2,665 places Jason Kelly in the 2,000–24,999 tier.
- 35%Probability of being accurate (35%)Identified Stack Overflow account for Jason Kelly with 2,665 reputation.
Investor score
No signal on this dimension.
What you likely need
Jason Kelly is a high-profile serial founder and CEO of Ginkgo Bioworks, a publicly traded synthetic biology company and YC S14 alum. His profile is dominated by deep technical and operational credibility in biotech, with significant capital raised and a successful public exit. His next priorities likely center on scaling Ginkgo's autonomous lab platform, deepening AI partnerships, and leveraging his public-company platform for further ecosystem influence.
Are these your current priorities?
We will tune and customize your Founder Festival experience to make sure you get invited to the events that would be most valuable to you.
- positioningDeepen and publicize the OpenAI collaboration on autonomous labs to attract additional enterprise AI partnerships and government contracts like the DOE Genesis Mission.
- tacticalAccelerate go-to-market for Ginkgo Cloud Labs' newest Cell-Free Protein Synthesis + Echo-MS offering by targeting pharma and biotech R&D teams with the $44/gene pricing signal.
- positioningIncrease public visibility of your co-founder role at Joyn Bio to signal breadth of your synthetic biology platform strategy beyond Ginkgo.
- hiringLeverage your YC S14 alumni status to recruit technical talent and identify acquisition targets within the YC biotech and AI portfolio.
- positioningBuild a clearer public narrative around Allonnia (your SEC-confirmed subsidiary) to attract strategic partners in environmental biotech.
- positioningContinue keynote appearances at pharma and AI conferences like PD2M to reinforce Ginkgo's position at the intersection of AI and drug discovery.
- positioningShare lessons from Ginkgo's 17-year journey from YC startup to public company through long-form content or a podcast to build founder community influence.